Omani experience with the use of factor IX Fc fusion protein

We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzadjali, Shireen I, Wali, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296795/
https://www.ncbi.nlm.nih.gov/pubmed/34290003
http://dx.doi.org/10.1136/bcr-2020-241154
Descripción
Sumario:We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.

Ejemplares similares